Clinical trial of tiotropium bromide combined with salmeterol fluticasone in the treatment of lung cancer patients with COPD in stable stage
10.13699/j.cnki.1001-6821.2024.08.002
- VernacularTitle:噻托溴铵联合沙美特罗氟替卡松治疗肺癌合并COPD稳定期患者的临床研究
- Author:
Zi-Lei XUAN
1
;
Rui-Yang DING
;
Wen-Zhu YANG
Author Information
1. 皖西卫生职业学院附属医院、六安市第二人民医院呼吸内科,安徽六安 237000
- Keywords:
tiotropium bromide;
salmeterol fluticasone;
lung cancer;
postoperation;
chronic obstructive pulmonary disease;
pulmonary function;
prognosis
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(8):1096-1100
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of tiotropium bromide combined with salmeterol fluticasone on postoperative lung function,blood gas index,and inflammatory response in patients with lung cancer complicated with stable chronic obstructive pulmonary disease(COPD).Methods Patients with lung cancer complicated with stable COPD after surgery were selected as research subjects and divided into control group and treatment group according to different treatment methods.The control group received 18 μg of tiotropium bromide powder for inhalation therapy,bid,for 3 days before surgery,while the treatment group received additional salmeterol inhalation powder treatment on basis of the control group's treatment,1 inhalation each time,bid,for 3 months.Lung function[forced vital capacity(FVC),forced expiratory volume in one second(FEV1),peak expiratory flow(PEF),FEV1/FVC],modified British Medical Research Council(mMRC)dyspnea scale,chronic obstructive pulmonary disease assessment test(CAT)score,quality of life questionnaire-C30(QLQ-C30)score,blood gas index[arterial oxygen pressure(PaO2),arterial blood oxygen saturation(SaO2),arterial carbon dioxide pressure(PaCO2)],inflammatory response indicators[interleukin-6(IL-6),interleukin-8(IL-8),tumor necrosis factor-α(TNF-α)],and occurrence of adverse drug reactions in the two groups with compared before and after treatment.Results Forty-seven and forty-five cases were included in the treatment and control groups,respectively.After treatment,the total effective rates of the treatment and control groups were 91.49％(43 cases/47 cases)and 75.56％(34 cases/45 cases)respectively,and the differences were statistically significant(P＜0.05).After treatment,the FEV1/FVC of the treatment and control groups were(0.62±0.10)％and(0.48±0.05)％;PEF were(1.94±0.20)and(1.02±0.11)L·s-1;mMRC scores were 2.01±0.25 and 2.26±0.23;CAT scores were 16.03±1.74 and 20.03±2.17;QLQ-C30 physical functioning scores were 79.31±8.92 and 75.04±7.86;PaO2 were(70.34±6.98)and(62.02±6.31)mmHg;IL-6 expression levels were(16.43±1.65)and(21.55±2.27)pg·mL-1.The above indexes in the treatment group compared with the control group were all statistically significant(all P＜0.05).The main adverse drug reactions in the treatment and control groups were skin allergies and nausea/vomiting,and the total incidence of adverse drug reactions in the treatment and control groups were 34.04％and 23.40％,with no statistically significant difference(P＞0.05).Conclusion Tiotropium bromide combined with salmeterol fluticasone is effective for patients with lung cancer complicated with stable COPD after surgery,which significantly improves their lung function,prognosis,and arterial blood gas levels.
